FORM 9

NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES

(or securities convertible or exchangeable into listed securities)

Name of Listed Issuer: Symbol(s):

|  |  |
| --- | --- |
| Verano Holdings Corp. (the “Issuer”). | VRNO |

Date: *February 1, 2022*. Is this an updating or amending Notice: Yes X No

If yes provide date(s) of prior Notices: *N/A*.

Issued and Outstanding Securities of Issuer Prior to Issuance:

*301,129,238.3038* *Class A subordinate voting shares in the capital of the Issuer (the “****Subordinate Voting Shares****”) and 245,658.5910 Class B proportionate voting shares in the capital of the Issuer (the “****Proportionate Voting Shares****”).*

**Pricing**

Date of news release announcing proposed issuance: *February 1, 2022*

Date of confidential request for price protection: *N/A.*

Closing Market Price on Day Preceding the news release: *$13.40.*

Day preceding request for price protection: *N/A*.

**Closing**

Number of securities to be issued:

*Approximately 36,554,484 Subordinate Voting Shares.*

Issued and outstanding securities following issuance: ­­­­­­­­­­­­­­­­­­­­

*Following the issuance, approximately 337,683,722.3038 Subordinate Voting Shares and 245,658.5910 Proportionate Voting Shares will be issued and outstanding.*

**Instructions:**

1. For private placements (including debt settlement), complete tables 1A and 1B in Part 1 of this form.
2. Complete Table 1A – Summary for all purchasers, excluding those identified in Item 8.
3. Complete Table 1B – Related Persons only for Related Persons
4. If shares are being issued in connection with an acquisition (either as consideration or to raise funds for a cash acquisition) please proceed to Part 2 of this form.
5. An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10 – Notice of Proposed Transaction
6. Post the completed Form 9 to the CSE website in accordance with *Policy 6 –* *Distributions.* In addition, the completed form must be delivered to [listings@thecse.com](mailto:listings@thecse.com) with an appendix that includes the information in Table 1B for ALL placees.

**Part 2. Acquisition**

1. Provide details of the assets to be acquired by the Issuer (including the location of the assets, if applicable). The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material:

*The Issuer entered into an arrangement agreement (the “****Arrangement Agreement****”), dated January 31, 2021, with Goodness Growth Holdings, Inc. (“****Goodness****”), pursuant to which the Issuer will acquire all of the issued and outstanding subordinate voting shares, multiple voting shares and super voting shares of Goodness (the "****Goodness Shares****"), with each Goodness shareholder expected to receive 0.22652 of a Subordinate Voting Share for each subordinate voting share (on an as-converted to subordinate voting share basis) of Goodness (the “****Acquisition****”). The Acquisition will be effected by way of a plan of arrangement under the Business Corporations Act (British Columbia).*

*The parties to the Arrangement Agreement are arms-length. The Arrangement Agreement provides for customary provisions, including covenants in respect of non-solicitation of alternative transactions, a right to match superior proposals, US$14.875 million reciprocal termination fees under certain circumstances and reciprocal expense reimbursement provisions in certain circumstances.*

*As a result of the Acquisition, the Issuer will acquire, among others, (i) a vertically integrated license in New York, which includes one cultivation license, four active dispensaries, and four additional dispensaries planned in high-traffic location; (ii) a vertically-integrated license in Minnesota which includes one cultivation license and eight active dispensaries; (iii) a cultivation facility and four medical dispensaries in New Mexico; and (iv) an 18-acre outdoor cultivation facility in Arizona.*

*Additional details of the Acquisition will be described in the management information circular and proxy statement (the “****Circular****”) that will be mailed to Goodness shareholders in connection with a special meeting of Goodness shareholders (the “****Meeting****”) to approve the Acquisition.*

*The Acquisition is subject to, among other things, the approvals of the Supreme Court of British Columbia, the approval of two-thirds of the votes cast by Goodness shareholders at the Meeting, receipt of U.S. regulatory approvals, including pursuant to the Hart–Scott–Rodino Antitrust Improvements Act and New York State regulatory requirements, and other customary conditions of closing. Additional details of the Transaction will be provided in the Circular.*

1. Provide details of the acquisition including the date, parties to and type of agreement (eg: sale, option, license etc.) and relationship to the Issuer. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the acquisition without reference to any other material:

*See response to Item 1 above.*

1. Provide the following information in relation to the total consideration for the acquisition (including details of all cash, securities or other consideration) and any required work commitments:
2. Total aggregate consideration in Canadian dollars:

*Pursuant to the Amalgamation Agreement, each Goodness shareholder is expected to receive 0.22652 of a Subordinate Voting Share for each share of Goodness, resulting in a transaction valued at approximately US$413 million.*

1. Cash: N/A*.*
2. Securities (including options, warrants etc.) and dollar value:

*Approximately 36,554,484 Subordinate Voting Shares and at a price of $13.40 per Subordinate Voting Share, having an aggregate value of approximately CAD$489.83 million.*

1. Other: *N/A.*
2. Expiry date of options, warrants, etc. if any: *N/A.*
3. Exercise price of options, warrants, etc. if any: *N/A.*
4. Work commitments: *N/A.*

4. State how the purchase or sale price was determined (e.g. arm’s-length negotiation, independent committee of the Board, third party valuation etc).

*The purchase price was determined by arm’s length negotiation and due diligence.*

5. Provide details of any appraisal or valuation of the subject of the acquisition known to management of the Issuer: *N/A.*

6. The names of parties receiving securities of the Issuer pursuant to the acquisition and the number of securities to be issued are described as follows:

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Name of** **Party (If not an individual, name all insiders of the** **Party)** | **Number and Type of Securities to be Issued** | **Dollar value per** **Security (CDN$)** | **Conversion price (if applicable)** | **Prospectus Exemption** | **Total Securities, Previously Owned, Controlled or Directed by Party** | **Describe relationship**  **to Issuer(1)** |
| Goodness Shareholders | Approx. 36,554,484 Subordinate Voting Shares | Approx. $13.40 | N/A | Section 2.11 of NI 45-106 | N/A | N/A |

1. Indicate if Related Person

7. Details of the steps taken by the Issuer to ensure that the vendor has good title to the assets being acquired:

*Issuer performed due diligence of Goodness and the Arrangement Agreement includes customary representations and warranties of Goodness.*

8. Provide the following information for any agent’s fee, commission, bonus or finder’s fee, or other compensation paid or to be paid in connection with the acquisition (including warrants, options, etc.): *N/A*

(a) Details of any dealer, agent, broker or other person receiving compensation in connection with the acquisition (name, and if a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): *N/A.*

(b) Cash *N/A.*

(c) Securities *N/A.*

(d) Other *N/A.*

1. Expiry date of any options, warrants etc. *N/A.*
2. Exercise price of any options, warrants etc. *N/A.*

9. State whether the sales agent, broker or other person receiving compensation in connection with the acquisition is a Related Person or has any other relationship with the Issuer and provide details of the relationship. *N/A.*

10. If applicable, indicate whether the acquisition is the acquisition of an interest in property contiguous to or otherwise related to any other asset acquired in the last 12 months. *N/A.*

**Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance on behalf of the Issuer.

1. As of the date hereof there is not material information concerning the Issuer which has not been publicly disclosed.
2. the Issuer has obtained the express written consent of each applicable individual to:

(a) the disclosure of their information to the Exchange pursuant to this Form or otherwise pursuant to this filing; and

(b) the collection, use and disclosure of their information by the Exchange in the manner and for the purposes described in Appendix A or as otherwise identified by the Exchange, from time to time

1. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CSE Policy 1).
2. All of the information in this Form 9 Notice of Issuance of Securities is true.

Dated \_February 1, 2022.

*Darren Weiss*   
Name of Director or Senior Officer

*(signed) "Darren Weiss"*   
Signature

Chief Legal Officer and General Counsel   
Official Capacity

**Appendix A**

**PERSONAL INFORMATION COLLECTION POLICY REGARDING FORM 9**

The Canadian Securities Exchange and its subsidiaries, affiliates, regulators and agents (collectively, “CSE or the “Exchange”) collect and use the information (which may include personal or other information) which has been provided in Form 9 for the following purposes:

• To determine whether an individual is suitable to be associated with a Listed Issuer;

• To determine whether an issuer is suitable for listing;

• To determine whether allowing an issuer to be listed or allowing an individual to be associated with a Listed Issuer could give rise to investor protection concerns or could bring the Exchange into disrepute;

• To conduct enforcement proceedings;

• To ensure compliance with Exchange Requirements and applicable securities legislation; and

• To fulfil the Exchange’s obligation to regulate its marketplace.

The CSE also collects information, including personal information, from other sources, including but not limited to securities regulatory authorities, law enforcement and self-regulatory authorities, regulation service providers and their subsidiaries, affiliates, regulators and agents. The Exchange may disclose personal information to these entities or otherwise as provided by law and they may use it for their own investigations.

The Exchange may use third parties to process information or provide other administrative services. Any third party will be obliged to adhere to the security and confidentiality provisions set out in this policy.

All personal information provided to or collected by or on behalf of The Exchange and that is retained by The Exchange is kept in a secure environment. Only those employees who need to know the information for the purposes listed above are permitted access to the information or any summary thereof. Employees are instructed to keep the information confidential at all times.

Information about you that is retained by the Exchange and that you have identified as inaccurate or obsolete will be corrected or removed.

If you wish to consult your file or have any questions about this policy or our practices, please write the Chief Privacy Officer, Canadian Securities Exchange, 220 Bay Street – 9th Floor, Toronto, ON, M5J 2W4.